Cargando…

Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin

An integrated analysis was performed with data from 4 phase 2 and phase 3 studies of tofogliflozin in which patients with type 2 diabetes mellitus received the sodium‐glucose cotransporter 2 inhibitor tofogliflozin for up to 24 weeks. Sex differences, baseline haemoglobin A1c (HbA1c) and serum uric...

Descripción completa

Detalles Bibliográficos
Autores principales: Ouchi, Motoshi, Oba, Kenzo, Kaku, Kohei, Suganami, Hideki, Yoshida, Akihiro, Fukunaka, Yasunori, Jutabha, Promsuk, Morita, Asuka, Otani, Naoyuki, Hayashi, Keitaro, Fujita, Tomoe, Suzuki, Tatsuya, Yasutake, Masahiro, Anzai, Naohiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887894/
https://www.ncbi.nlm.nih.gov/pubmed/29171930
http://dx.doi.org/10.1111/dom.13170
_version_ 1783312408904728576
author Ouchi, Motoshi
Oba, Kenzo
Kaku, Kohei
Suganami, Hideki
Yoshida, Akihiro
Fukunaka, Yasunori
Jutabha, Promsuk
Morita, Asuka
Otani, Naoyuki
Hayashi, Keitaro
Fujita, Tomoe
Suzuki, Tatsuya
Yasutake, Masahiro
Anzai, Naohiko
author_facet Ouchi, Motoshi
Oba, Kenzo
Kaku, Kohei
Suganami, Hideki
Yoshida, Akihiro
Fukunaka, Yasunori
Jutabha, Promsuk
Morita, Asuka
Otani, Naoyuki
Hayashi, Keitaro
Fujita, Tomoe
Suzuki, Tatsuya
Yasutake, Masahiro
Anzai, Naohiko
author_sort Ouchi, Motoshi
collection PubMed
description An integrated analysis was performed with data from 4 phase 2 and phase 3 studies of tofogliflozin in which patients with type 2 diabetes mellitus received the sodium‐glucose cotransporter 2 inhibitor tofogliflozin for up to 24 weeks. Sex differences, baseline haemoglobin A1c (HbA1c) and serum uric acid (UA) levels, and log(10)‐transformed urinary N‐acetyl‐β‐D‐glucosaminidase ratio were significantly correlated with the reduction in serum UA levels at both 4 and 24 weeks in multivariate analysis (respectively, P < .0001). The decrease in HbA1c levels was greatest in the group with the highest baseline HbA1c level (quartile 4; HbA1c > 8.6%) and lowest in the group with the lowest baseline HbA1c level (quartile 1; HbA1c ≤ 7.4%). The decrease in serum UA levels was greatest in the quartile 1 group and lowest in the quartile 4 group. In most groups, the maximum decrease in serum UA levels was seen in the first 4 weeks, while the maximum decrease in HbA1c was seen at week 24. Thus, serum UA levels were significantly decreased in patients with moderate HbA1c levels.
format Online
Article
Text
id pubmed-5887894
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-58878942018-04-12 Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin Ouchi, Motoshi Oba, Kenzo Kaku, Kohei Suganami, Hideki Yoshida, Akihiro Fukunaka, Yasunori Jutabha, Promsuk Morita, Asuka Otani, Naoyuki Hayashi, Keitaro Fujita, Tomoe Suzuki, Tatsuya Yasutake, Masahiro Anzai, Naohiko Diabetes Obes Metab Brief Reports An integrated analysis was performed with data from 4 phase 2 and phase 3 studies of tofogliflozin in which patients with type 2 diabetes mellitus received the sodium‐glucose cotransporter 2 inhibitor tofogliflozin for up to 24 weeks. Sex differences, baseline haemoglobin A1c (HbA1c) and serum uric acid (UA) levels, and log(10)‐transformed urinary N‐acetyl‐β‐D‐glucosaminidase ratio were significantly correlated with the reduction in serum UA levels at both 4 and 24 weeks in multivariate analysis (respectively, P < .0001). The decrease in HbA1c levels was greatest in the group with the highest baseline HbA1c level (quartile 4; HbA1c > 8.6%) and lowest in the group with the lowest baseline HbA1c level (quartile 1; HbA1c ≤ 7.4%). The decrease in serum UA levels was greatest in the quartile 1 group and lowest in the quartile 4 group. In most groups, the maximum decrease in serum UA levels was seen in the first 4 weeks, while the maximum decrease in HbA1c was seen at week 24. Thus, serum UA levels were significantly decreased in patients with moderate HbA1c levels. Blackwell Publishing Ltd 2018-01-08 2018-04 /pmc/articles/PMC5887894/ /pubmed/29171930 http://dx.doi.org/10.1111/dom.13170 Text en © 2017 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Brief Reports
Ouchi, Motoshi
Oba, Kenzo
Kaku, Kohei
Suganami, Hideki
Yoshida, Akihiro
Fukunaka, Yasunori
Jutabha, Promsuk
Morita, Asuka
Otani, Naoyuki
Hayashi, Keitaro
Fujita, Tomoe
Suzuki, Tatsuya
Yasutake, Masahiro
Anzai, Naohiko
Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin
title Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin
title_full Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin
title_fullStr Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin
title_full_unstemmed Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin
title_short Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin
title_sort uric acid lowering in relation to hba1c reductions with the sglt2 inhibitor tofogliflozin
topic Brief Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887894/
https://www.ncbi.nlm.nih.gov/pubmed/29171930
http://dx.doi.org/10.1111/dom.13170
work_keys_str_mv AT ouchimotoshi uricacidloweringinrelationtohba1creductionswiththesglt2inhibitortofogliflozin
AT obakenzo uricacidloweringinrelationtohba1creductionswiththesglt2inhibitortofogliflozin
AT kakukohei uricacidloweringinrelationtohba1creductionswiththesglt2inhibitortofogliflozin
AT suganamihideki uricacidloweringinrelationtohba1creductionswiththesglt2inhibitortofogliflozin
AT yoshidaakihiro uricacidloweringinrelationtohba1creductionswiththesglt2inhibitortofogliflozin
AT fukunakayasunori uricacidloweringinrelationtohba1creductionswiththesglt2inhibitortofogliflozin
AT jutabhapromsuk uricacidloweringinrelationtohba1creductionswiththesglt2inhibitortofogliflozin
AT moritaasuka uricacidloweringinrelationtohba1creductionswiththesglt2inhibitortofogliflozin
AT otaninaoyuki uricacidloweringinrelationtohba1creductionswiththesglt2inhibitortofogliflozin
AT hayashikeitaro uricacidloweringinrelationtohba1creductionswiththesglt2inhibitortofogliflozin
AT fujitatomoe uricacidloweringinrelationtohba1creductionswiththesglt2inhibitortofogliflozin
AT suzukitatsuya uricacidloweringinrelationtohba1creductionswiththesglt2inhibitortofogliflozin
AT yasutakemasahiro uricacidloweringinrelationtohba1creductionswiththesglt2inhibitortofogliflozin
AT anzainaohiko uricacidloweringinrelationtohba1creductionswiththesglt2inhibitortofogliflozin